Gabapentin for Adults With Neuropathic Pain: A Review

Context
Neuropathic pain is complex and difficult to treat. It includes conditions such as painful diabetic neuropathy, postherpetic neuralgia, spinal cord injury-related neuropathic pain, trigeminal neuralgia, and fibromyalgia. Treatment typically includes both pharmaceutical and physical therapies. Gabapentin is one pharmaceutical that is used for neuropathic pain.

Technology
Gabapentin, an anticonvulsant originally developed for the treatment of epilepsy, is used off-label for treating neuropathic pain. It is thought to work by binding to calcium channels and modulating calcium influx or by blocking new synapse formation, thus inhibiting the transmission of nerve signals in the brain.

Issue
There have been reports of misuse of gabapentin, and also of black-market sales and trading in correctional facilities. There is also evidence that, in high doses, gabapentin may be associated with sedative and dissociative or psychedelic effects. A review of the clinical effectiveness of gabapentin compared with tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, and pregabalin for treating neuropathic pain; the evidence on the abuse or misuse potential of these medications; and the guidelines for the use of gabapentin will help to inform treatment decisions for patients with neuropathic pain.

Methods
A limited literature search was conducted of key resources, and titles and abstracts of the retrieved publications were reviewed. Full-text publications were evaluated for final article selection according to predetermined selection criteria (population, intervention, comparator, outcomes, and study designs).

Key Messages
- For the short-term treatment of painful diabetic neuropathy, postherpetic neuralgia, and fibromyalgia, gabapentin may be as effective as tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, or pregabalin (based on indirect evidence).
- No information was found on the comparative effectiveness of the treatments for other types of neuropathic pain.
- Pregabalin and gabapentin may be used as recreational drugs, but the prevalence of and risk of misuse among patients prescribed drugs to manage neuropathic pain is not known.
- United Kingdom guidelines support the use of gabapentin, amitriptyline, duloxetine, or pregabalin as first-line therapy for neuropathic pain, except for patients with trigeminal neuralgia.

Results
The literature search identified 792 citations, plus 7 articles identified from other sources. After screening the abstracts, 57 studies were deemed potentially relevant, and 12 reports were summarized — 3 systematic reviews, 1 randomized controlled trial, 6 non-randomized studies, and 2 guidelines.

DISCLAIMER: The information in this Report in Brief is intended to help health care decision-makers, patients, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. The information in this Report in Brief should not be used as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of the Report in Brief to ensure that its contents are accurate, complete, and up-to-date, CADTH does not make any guarantee to that effect. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or as a result of the use (or misuse) of any information contained in or implied by the information in this Report in Brief.

CADTH takes sole responsibility for the final form and content of this Report in Brief. The statements, conclusions, and views expressed herein do not necessarily represent the view of Health Canada or any provincial or territorial government. Production of this Report in Brief is made possible through a financial contribution from Health Canada.

RC0594